Diabetes My Way: your home for online diabetes support
Research type
Research Study
Full title
Diabetes My Way: your home for online diabetes support
IRAS ID
261268
Contact name
Martin Rutter
Contact email
Sponsor organisation
University of Manchester
ISRCTN Number
ISRCTN12014792
Duration of Study in the UK
1 years, 5 months, 31 days
Research summary
Clinical problem: Type 2 diabetes (T2D) affects ~7% of the UK population. Suboptimal management of T2D leads to serious complications such as heart attacks, kidney failure and blindness. Poor patient knowledge about T2D contributes to sub-optimal levels of glucose and cardiovascular risk factors. There is major variation in the level of knowledge that patients have about diabetes; major variation in the quality of diabetes care across general practices in Greater Manchester (GM); practical and financial challenges for delivering behavioral interventions supporting healthier lifestyles; major blocks in clinical care because of diabetes-related psychological distress - all compounded by low attendance rates in clinics and structured education in some patient groups.
Aim: To assess whether digital interventions improve T2D self-management across GM.
Methods: Between April 2019-March 2020, digital interventions will be offered to all patients with T2D across GM including access to educational resources, their medical records, personalised care planning, goal-setting tools, personalised care quality reporting against Care Standards and glucose monitoring displays through DiabetesMyWay (DMW). Sub-groups of patients will also have access to online behavioural interventions (Oviva; Changing Health), cognitive intervention (MyCognition); targeted incentives to improve clinic attendance rates (BillawayHealth) and more flexible clinic interactions with patients (Smart Care Videoconferencing). Clinicians will have access to patient data including information on the impact of intervention enabling personalised treatment plans.
Evaluation: The effectiveness of DMW, Oviva and Changing Health, MyCognition and BillawayHealth will be assessed by assessing within person changes in outcomes before vs. after intervention. The main focus will be on changes in glucose control and cardiovascular risk factors. There will be assessments of usability another patient reported outcomes. Outcomes will be assessed across all patient groups and in ethnic minority and socially deprived subgroups.
Expected benefits: If the Intervention is found to support self-care and clinical care in T2D across GM then this evidence could justify roll out of these interventions across the NHS in England.
REC name
North West - Greater Manchester South Research Ethics Committee
REC reference
19/NW/0365
Date of REC Opinion
26 Jun 2019
REC opinion
Favourable Opinion